Previous 10 | Next 10 |
Gainers: Five Prime Therapeutics (FPRX) +78%, Ampio Pharmaceuticals (AMPE) +10%, Soligenix (SNGX) +7%.Losers: BioVie (BIVI) -29%, Schrodinger (SDGR) -25%, KemPharm (KMPH) -19%, Anchiano Therapeutics (ANCN) -15%, AbCellera Biologics (...
Amgen (AMGN) and Five Prime Therapeutics (FPRX) ink merger agreement under which, AMGN will acquire Five Prime for $38.00/share in cash, representing an equity value of ~$1.9B. This acquisition adds Five Prime's innovative pipeline to Amgen's oncology portfolio with a promising late...
Acquisition Includes Bemarituzumab, A Phase 3 Ready, First-In-Class Program For Gastric Cancer, the Third Leading Cause of Cancer Mortality Worldwide Bemarituzumab is a Strong Strategic Fit With Amgen’s Innovative Oncology Portfolio Amgen to Host Investor Call a...
Amgen To Acquire Five Prime Therapeutics For $1.9 Billion in Cash Acquisition Includes Bemarituzumab, A Phase 3 Ready, First-In-Class Program For Gastric Cancer, the Third Leading Cause of Cancer Mortality Worldwide Bemarituzumab is a Strong Strategic Fit With Amgen's Innova...
Five Prime Therapeutics, Inc. (NASDAQ: FPRX), will report its fourth quarter and full year 2020 operational and financial results on Wednesday, March 10, 2021 after the U.S. financial markets close. Five Prime will also host a conference call and live audio webcast that same day at ...
Five Prime Therapeutics, Inc. (NASDAQ: FPRX) today announced that Tom Civik, President and Chief Executive Officer, and Helen Collins, M.D., Executive Vice President and Chief Medical Officer are scheduled to participate in a fireside chat at the Cowen 41 st Annual Health Care C...
Five Prime Therapeutics, Inc. (NASDAQ: FPRX) today announced that Tom Civik, President and Chief Executive Officer, and Helen Collins, M.D., Executive Vice President and Chief Medical Officer are scheduled to participate in a fireside chat at the virtual SVB Leerink 10 th Annual...
Healthcare lagged the broader market last year, but that can change this year. A cyclical upturn as the pandemic abates and pent-up demand can boost healthcare. Best positioned are industry groups within healthcare that can achieve secular growth beyond the cyclical rise. Biot...
Five Prime Therapeutics, Inc. (NASDAQ: FPRX) today announced that Tom Civik, President and Chief Executive Officer, and Helen Collins, M.D., Executive Vice President and Chief Medical Officer, are scheduled to participate in a fireside chat at the virtual Guggenheim Healthcare Talks...
The following slide deck was published by Five Prime Therapeutics, Inc. in conjunction with this event. For further details see: Five Prime Therapeutics (FPRX) Presents at ASCO Gastrointestinal Cancer Symposium 2021 - Slideshow
News, Short Squeeze, Breakout and More Instantly...
Five Prime Therapeutics Inc. Company Name:
FPRX Stock Symbol:
NASDAQ Market:
Five Prime Therapeutics Inc. Website:
Amgen Successfully Completes Acquisition Of Five Prime Therapeutics PR Newswire THOUSAND OAKS, Calif. , April 16, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it has successfully completed its previously announced tender offer to purchase all out...
Amgen (NASDAQ: AMGN) recently announced plans to acquire Five Prime Therapeutics (NASDAQ: FPRX) for approximately $1.9 billion. The deal gives Amgen rights to bemarituzumab, which has made it through phase 2 testing. In this video from Motley Fool Live , recorded on ...
Five Prime Therapeutics, Inc. (NASDAQ: FPRX) announced today that it has canceled its fourth quarter and full year 2020 earnings conference call, which was previously scheduled for Wednesday, March 10, 2021 at 1:30 p.m. PT / 4:30 p.m. ET. The cancellation is the result of the co...